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Meta-analysis of Gene-Level Associations
for Rare Variants Based on Single-Variant Statistics
Yi-Juan Hu,1 Sonja I. Berndt,2 Stefan Gustafsson,3 Andrea Ganna,3,4 Genetic Investigation of
ANthropometric Traits (GIANT) Consortium, Joel Hirschhorn,5,6,7 Kari E. North,8 Erik Ingelsson,3,9
and Dan-Yu Lin10,*
Meta-analysis of genome-wide association studies (GWASs) has led to the discoveries of many common variants associatedwith complex
human diseases. There is a growing recognition that identifying ‘‘causal’’ rare variants also requires large-scale meta-analysis. The fact
that association tests with rare variants are performed at the gene level rather than at the variant level poses unprecedented challenges
in the meta-analysis. First, different studies may adopt different gene-level tests, so the results are not compatible. Second, gene-level
tests require multivariate statistics (i.e., components of the test statistic and their covariance matrix), which are difficult to obtain. To
overcome these challenges, we propose to perform gene-level tests for rare variants by combining the results of single-variant analysis
(i.e., p values of association tests and effect estimates) from participating studies. This simple strategy is possible because of an insight
that multivariate statistics can be recovered from single-variant statistics, together with the correlation matrix of the single-variant test
statistics, which can be estimated from one of the participating studies or from a publicly available database.We show both theoretically
and numerically that the proposed meta-analysis approach provides accurate control of the type I error and is as powerful as joint anal-
ysis of individual participant data. This approach accommodates any disease phenotype and any study design and produces all
commonly used gene-level tests. An application to the GWAS summary results of the Genetic Investigation of ANthropometric Traits
(GIANT) consortium reveals rare and low-frequency variants associated with human height. The relevant software is freely available.Introduction
Meta-analysis, which combines summary statistics from a
series of independent studies, plays an increasingly impor-
tant role in human genetics research.1–3 Obtaining sum-
mary statistics is much more appealing than collecting
individual participant data because it protects the privacy
of study participants, avoids cumbersome integration of
genotype and phenotype data from different studies, and
increases the number of available studies. In addition,
meta-analysis of summary statistics is statistically as
efficient as joint analysis of individual participant data.4,5
Thus, meta-analysis has become a norm in GWASs, result-
ing in the discoveries of numerous common variants
associated with complex human diseases.
Recent advances in next-generation sequencing technol-
ogies have made it possible to extend association studies to
rare variants, which are expected to have larger effects on
complex human diseases than common variants.6,7 To
enrich association signals and reduce the penalty of multi-
ple testing, investigators typically perform gene-level asso-
ciation tests by aggregating the mutation information of
the rare variants within a gene. The simplest approach is
the burden test, which calculates a single burden score
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minor allele frequencies (MAFs) and assesses the disease
association with the burden score.8–12 A second approach
is the variable threshold (VT) method, which performs a
burden test by aggregating the variants whose MAFs are
lower than a threshold and minimizes the p value over
observed MAF thresholds.11,12 A third approach is the
variance-component testing, which is aimed at detecting
the presence of both deleterious and protective variants
in the same gene.13–15 Gene-level tests for rare variants
have limited power because only a small fraction of study
subjects carry any mutation within a gene and there are
high background rates of neutral variation even in
‘‘causal’’ genes. Thus, there is a growing recognition that
identifying ‘‘causal’’ rare variants would require large-scale
meta-analysis.
It is much more challenging to perform meta-analysis of
rare variants than to do so with common variants. First,
different studies may adopt different types of gene-level
tests, so the test results are not compatible. Second, even
if the same type of test is adopted, different studies may
use different gene annotations, different classes of vari-
ants, or different MAFs. Third, meta-analysis is restricted
to the specific gene-level test results provided by the
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other tests. Fourth, VT and variance-component tests are
multivariate in nature, so the meta-analysis requires multi-
variate summary statistics (i.e., the components of the test
statistic and their covariance matrix); combining the
p values of multivariate tests would lose power. Although
these difficulties may be alleviated by following a common
protocol in a well-organized consortium, the tremendous
effort required to execute such a protocol will seriously
limit the use of meta-analysis.
To circumvent these problems, we propose to collate
only the results of single-variant analysis from partici-
pating studies and leave the choices of the gene-level
test, annotation, variant class, and MAFs to the discretion
of the meta-analyst. This attractive strategy is possible
because of two important insights. First, all commonly
used gene-level test statistics can be constructed from the
score vector and the corresponding information matrix
for testing the global null hypothesis that none of the var-
iants in the gene is associated with the disease phenotype.
Second, the score vector and information matrix can be
recovered from the single-variant results, namely the
p values based onWald, score, or likelihood-ratio (LR) tests
and the effect estimates, together with the correlation
matrix of the single-variant test statistics. The correlation
matrix can be estimated from one of the participating
studies, perhaps the study that the meta-analyst is directly
involved with. If such a study is not available, the cor-
relation matrix can be approximated by the correlation
matrix of the genotypes from a publicly available database,
such as the 1000 Genomes, HapMap, or NHLBI Exome
Sequencing Project (ESP).16–18 We show both theoretically
and numerically that the proposedmeta-analysis approach
provides accurate control of the type I error and is as
powerful as joint analysis of individual participant data.
This approach can accommodate any disease phenotype
and any study design and produce all commonly used
gene-level tests.
The proposed approach not only greatly facilitates meta-
analysis of sequencing studies but also provides a way to
exploit the massive GWAS data. Many GWASs have
focused on common variants but have also produced
single-variant results for rare and low-frequency variants,
which have seldom been exploited. Our approach can be
used to combine such single-variant results and perform
gene-level association tests. Single-variant results are
available in NCBI’s database of Genotypes and Phenotypes
(dbGaP) and can be freely accessed without applying for
controlled access to individual participant data. Thus, the
proposed approach is far more useful than any methods
that require multivariate summary statistics or individual
participant data.
This work was motivated by the GIANT project.19,20 The
GIANT consortium successfully identified a number of
common variants for anthropometric traits.19,20 It also
collected single-variant summary results for rare and low-
frequency variants. Single-variant meta-analysis of those
results would have little power. Therefore, we wished toThe Amerconduct gene-based meta-analysis for those variants.
Because the consortium involved a very large number of
cohorts, it would not be feasible to ask individual investi-
gators to perform gene-level association tests and provide
multivariate summary statistics. Therefore, we applied
the proposed methods to the existing single-variant
summary results by using one of the participating cohorts,
the Atherosclerosis Risk in Communities (ARIC) Study,21 as
the internal reference. We identified several genes con-
taining variants for extreme height that were not detect-
able by single-variant meta-analysis.Material and Methods
Suppose that we are interested in m rare variants within a gene.
(We use the term ‘‘rare variants’’ to encompass both low-frequency
and truly rare variants.) The genotypes are represented by
G ¼ ðG1;.;GmÞT, where Gj is the number of minor alleles at the
jth variant site. Let Y denote the trait of interest, which can be
continuous or discrete, and let X denote a set of covariates (e.g.,
demographical variables and principal components for ancestry)
plus the unit component. We relate Y to G and X through a gener-
alized linear model by specifying the conditional density function
of Y given G and X as
exp

y

bTGþ gTX bbTGþ gTX
aðfÞ þ cðy;fÞ

; (Equation 1)
where b ¼ ðb1;.; bmÞT and g are regression parameters, f is a
dispersion parameter, and a, b, and c are specific functions. Denote
b0ðzÞ ¼ dbðzÞ=dz and b00ðzÞ ¼ d2bðzÞ=dz2. For the linear model,
aðfÞ ¼ s2, bðzÞ ¼ ð1=2Þz2, b0ðzÞ ¼ z, and b00ðzÞ ¼ 1. For the logistic
regression model, aðfÞ ¼ 1, bðzÞ ¼ logð1þ ezÞ, b0ðzÞ ¼ ez=ð1þ ezÞ,
and b00ðzÞ ¼ ez=ð1þ ezÞ2.
For a study with n unrelated subjects, the data consist of
ðYi;Gi;XiÞ ði ¼ 1;.;nÞ. The score statistic for testing the null
hypothesis H0 : b ¼ 0 is
U ¼ abf1Xn
i¼1

Yi  b0
bgTXiGi;
where bg and bf are the restricted maximum likelihood estimators
(MLEs) of g and f under H0. For the linear model, bg ¼
ðPni¼1XiXTi Þ1Pni¼1YiXi and aðbfÞ ¼ bs2 ¼ n1Pni¼1ðYi  bgTXiÞ2.
Under H0, U is asymptotically m-variate normal with mean
0 and covariance matrix
V ¼ abf1"Xn
i¼1
b00
bgTXiGiGTi 
(Xn
i¼1
b00
bgTXiGiXTi
)

(Xn
i¼1
b00
bgTXiXiXTi
)1(Xn
i¼1
b00
bgTXiXiGTi
)#
;
(Equation 2)
which is the information matrix evaluated at b ¼ 0, g ¼ bg, and
f ¼ bf.
Suppose that we wish to combine the results of L independent
studies. For l ¼ 1;.;L, let UðlÞ and VðlÞ denote the values of U
and V from the lth study. It is not necessary for all m variants to
be present in all studies. If the lth study contains no mutation at
a particular variant site, we simply set the corresponding entries
in U ðlÞ and V ðlÞ to 0. Defineican Journal of Human Genetics 93, 236–248, August 8, 2013 237
U ¼
XL
l¼1
U ðlÞ;V ¼
XL
l¼1
V ðlÞ:
Under H0, U is asymptotically m-variate normal with mean 0
and covariance matrix V . If we allow g and f of Equation 1 to
be different among the L studies, then U is exactly the score
statistic for testing H0 in the joint likelihood of the individual
participant data of the L studies.5 Thus, meta-analysis based on
score statistics is equivalent to joint analysis of individual partici-
pant data.
GivenU andV, we can construct all commonly used gene-based
association tests for rare variants. Specifically, define the
(weighted) burden score xTG, where x is an m-vector of weights
that depend on the MAFs.8–12 The score statistic for testing the
disease association with the burden score can be expressed as
~U ¼ xTU, whose variance is ~V ¼ xTVx.12 The test statistic
T ¼ ~U=~V1=2 is referred to the standard normal distribution. If
we are interested in K burden scores with vectors of weights
x1;.; xK, then we calculate ~Uk ¼ xTkU ðk ¼ 1;.;KÞ. Under the
null hypothesis of no association, ð~U1;.; ~UKÞT is asymptotically
K-variate normal with mean 0 and covariance matrix
f~Vkl; k; l ¼ 1;.;Kg, where ~Vkl ¼ xTkVxl. The p value for the
maximum statistic Tmax ¼maxk¼1;.;K
~Uk=~V1=2kk is determined
by the multivariate normal distribution of ð~U1;.; ~UKÞT.12 The
SKAT statistic can be written as Q ¼ UTWU; whereW is a diagonal
weight matrix that depends on the MAFs through a beta func-
tion.15 The null distribution of Q is determined by
Pm
j¼1ljc
2
1;j;
where l1;.; lm are the eigenvalues of V
1=2
WV
1=2
and
c21;1;.;c
2
1;m are independent c
2
1 random variables.
The abovemeta-analysis approach is predicated on the availabil-
ity of U and V for each study. Note that U is anm3 1 vector and V
is an m 3 m matrix. Such multivariate summary statistics are not
available in published papers or public databases. Even for a
well-organized consortium, it is logistically difficult to generate
such multivariate summary statistics. We show below that it is
possible to recover U and V for each study from the (univariate)
single-variant statistics provided that the correlation matrix of U
can be estimated from an internal or external reference panel.
For each study, let Uj denote the j
th component of U and Vjl
denote the ðj; lÞth element of V. Let Zj denote the standard-normal
statistic for testing the null hypothesis Hj : bj ¼ 0 under Equation
1 with bTG replaced by bjGj. For the score, Wald, and LR tests, Zj
takes the forms of Uj=V
1=2
jj ,
bbj=sej, and signðbbjÞ ﬃﬃﬃﬃﬃﬃLRp , respectively,
where bbj is the MLE of bj, sej is the standard error of bbj, and LR is
the likelihood ratio statistic. The three forms of Zj are asymptoti-
cally equivalent. When Uj is not available but Zj is, we approxi-
mate Uj by bUj ¼ wjZj;
where wj is an approximation to V
1=2
jj . Write
bU ¼ ðbU 1;.; bUmÞT,
which is asymptoticallym-variate normal withmean 0 and covari-
ance matrix bV ¼ f bVjl; j; l ¼ 1;.;mg, wherebV jl ¼ wjRjlwl;
and R ¼ fRjl; j; l ¼ 1;.;mg is the covariance or correlation matrix
of ðZ1;.;ZmÞT. We substitute bU and bV for U and V in each study
and perform the aforementioned gene-based association tests. If Zj
is the score test and wj ¼ V1=2jj , then bU j ¼ Uj. If Zj is the Wald or LR
test or wjsV
1=2
jj , then
bU jsUj; however, meta-analysis based on bU
238 The American Journal of Human Genetics 93, 236–248, August 8and bV will still have correct type I error as long as the correlation
matrix R is correctly estimated for each study.
We show in Appendix A that the correlation matrix R is deter-
mined primarily by the correlation matrix of G. Specifically, two
studies with the same correlation matrix of G will have the same
R if covariates are absent or independent of genotypes and will
have approximately the same R even if covariates are correlated
with genotypes. Thus, we can use the value of R from one study
to approximate the values of R in other studies with similar linkage
disequilibrium (LD) structures. We refer to such a study as the
internal reference. If no internal reference is available, we resort
to an external reference panel such as the HapMap, 1000
Genomes, or ESP.16–18 It is desirable to use an internal or external
reference panel that has the same ancestry as the target study to
ensure similar LD structures.
We assume that the summary statistics that are available for
meta-analysis contain the parameter estimates and p values of
individual variants, i.e., ðbbj; pjÞ ðj ¼ 1;.;mÞ, for each study, where
pj is the (two-sided) p value based on theWald, score, or LR test.We
recover the test statistic Zj by signðbbjÞF1ð1 pj=2Þ, where F is the
standard-normal distribution function. (We replace pj=2 by pj in
the formula if the p value is based on a one-sided test.)
The standard error estimates sejs are usually contained in the
summary results. If not, we recover sej by bbj=Zj. This approxima-
tion is exact if Zj is the Wald statistic and is accurate if Zj is the
score or LR statistic. Recall that sej is the standard error estimate
of bbj and thatVjj is the variance estimate ofUj. It is reasonable to set
wj ¼ 1=sej because 1=sej is the same as V1=2jj except that the infor-
mation matrix used to calculate sej is evaluated at the MLEs of
bj, g, and f whereas the information matrix used to calculate Vjj
is evaluated at b ¼ 0 and the restricted MLEs of g and f. For rare
variants, the sejs may be unstable. If an internal reference study
is available, we may set wj ¼ fðn=nÞVjjg1=2, where n and Vjj are
the values of n and Vjj for the reference study, the reason being
that Vjj is approximately proportional to the sample size when
the trait variance (for continuous Y) or the case-control ratio (for
binary Y) is fixed. If the trait variances or the case-control ratios
are possibly different between the reference and target studies,
we replace ðn=nÞ1=2 by the median of fðsel =selÞ; l ¼ 1;.;Mg,
where M is the total number of variants that are genotyped and
sel is the value of sel in the reference study. The median provides
a stable estimate for the ratio of the two standard errors, allowing
the trait variances or the case-control ratios to be different
between studies. If no internal reference is available, we set
wj ¼ ðseyj Þ13medianl¼1;.;Mðseyl =selÞ, where seyl is the value of sel
in the largest study of the meta-analysis.
In short, the summary results contain minimally the p values
and effect estimates, from which we recover the standard-normal
statistics. The standard error estimates are optional.When they are
not available, we set sej ¼ bbj=Zj. If an internal reference is avail-
able, we set wj ¼ V1=2jj 3medianl¼1;.;Mðsel =selÞ and estimate R by
the correlation matrix of the score statistics in the internal refer-
ence; otherwise, we set wj ¼ ðseyj Þ13medianl¼1;.;Mðseyl =selÞ and
estimate R by the correlation matrix of the SNP genotypes in the
external reference.Results
Simulation Studies
We carried out extensive simulation studies to evaluate the
performance of the proposed methods in realistic settings., 2013
Table 1. Correlation Matrices for OR2T29
Correlation Matrix of Genotypes
rs142202454 rs199706827 rs200777722 rs200169450 rs201345491 rs200919674 rs201896684
rs142202454 1 0.141 0.003 0.129 0.109 0.110 0.120
rs199706827 1 0.292 0.656 0.541 0.523 0.581
rs200777722 1 0.128 0.007 0.007 0.025
rs200169450 1 0.496 0.555 0.799
rs201345491 1 0.829 0.613
rs200919674 1 0.672
rs201896684 1
Correlation Matrix of Test Statistics with Case-Control Ratio of 1
rs142202454 rs199706827 rs200777722 rs200169450 rs201345491 rs200919674 rs201896684
rs142202454 1 0.136 0.004 0.124 0.104 0.104 0.115
rs199706827 1 0.293 0.646 0.531 0.511 0.568
rs200777722 1 0.125 0.012 0.012 0.020
rs200169450 1 0.483 0.543 0.793
rs201345491 1 0.825 0.602
rs200919674 1 0.663
rs201896684 1
Correlation Matrix of Test Statistics with Case-Control Ratio of 2
rs142202454 rs199706827 rs200777722 rs200169450 rs201345491 rs200919674 rs201896684
rs142202454 1 0.132 0.004 0.120 0.101 0.101 0.111
rs199706827 1 0.292 0.640 0.524 0.504 0.562
rs200777722 1 0.124 0.011 0.012 0.020
rs200169450 1 0.476 0.537 0.790
rs201345491 1 0.822 0.597
rs200919674 1 0.658
rs201896684 1To cover different MAF and LD spectrums, we chose two
genes on chromosome 1 (OR2T29 and LDLRAD1) and
focused on SNPs with MAFs <5%. According to the WHI
African-American data from the ESP,18 there are seven
SNPs in OR2T29, with MAFs of 0.003, 0.030, 0.003, 0.036,
0.017, 0.017, and 0.036 for rs142202454, rs199706827,
rs200777722, rs200169450, rs201345491, rs200919674,
and rs201896684 and genotype correlations shown in the
upper block of Table 1. This gene contains a few relatively
common SNPs that are in modest LD. There are eight
SNPs in LDLRAD1, with MAFs of 0.021, 0.001, 0.001,
0.017, 0.001, 0.007, 0.007, and 0.001 for rs143619888,
rs150468103, rs141759859, rs149768061, rs147345740,
rs145889899, rs142900519, and rs149114405 and geno-
type correlations shown in the upper block of Table 2.
This gene containsmostly rare SNPs, the correlations being
very low except for one pair. We generated the SNP geno-
types of the two genes via GWAsimulator22 to mimic the
MAFs and LD patterns observed in the ESP WHI data.The AmerWe conducted meta-analysis of three studies with 2,000,
1,500, and 1,000 subjects, referred to as study 1, study 2,
and study 3, respectively. We considered the situations
both with and without an internal reference. For the
former, study 1 was treated as the internal reference. For
the latter, we generated an ‘‘external’’ reference panel
with 1,000 subjects (mimicking the ESP WHI data). We
simulated quantitative traits from the linear regression
model Y ¼ bSþ 0:2Xþ e and binary traits from the logistic
regression model logfPðY ¼ 1Þ=PðY ¼ 0Þg ¼ bSþ 0:2X,
where S is the total number of mutations the subject carries
in the gene, X is a normal random variable with mean 0.2S
and variance one, and ε is zero-mean normal with variance
s2. Note that X is correlated with S and may represent a
principal component for ancestry. To allow the possibil-
ities of both equal and unequal error variances among
studies, we set s2 ¼ 1:0 in study 1 and varied the values
of s2 in the other two studies. For binary traits, we obtained
an equal number of cases and controls for study 1 andican Journal of Human Genetics 93, 236–248, August 8, 2013 239
Table 2. Correlation Matrices for LDLRAD1
Correlation Matrix of Genotypes
rs143619888 rs150468103 rs141759859 rs149768061 rs147345740 rs145889899 rs142900519 rs149114405
rs143619888 1 0.005 0.005 0.019 0.005 0.012 0 0
rs150468103 1 0.001 0.005 0.001 0.003 0 0
rs141759859 1 0.005 0.002 0.003 0.003 0
rs149768061 1 0.005 0.639 0.011 0
rs147345740 1 0.003 0.003 0
rs145889899 1 0.007 0
rs142900519 1 0
rs149114405 1
Correlation Matrix of Test Statistics with Case-Control Ratio of 1
rs143619888 rs150468103 rs141759859 rs149768061 rs147345740 rs145889899 rs142900519 rs149114405
rs143619888 1 0.005 0.005 0.021 0.005 0.014 0.001 0.001
rs150468103 1 0.001 0.005 0.001 0.003 0 0
rs141759859 1 0.005 0.001 0.003 0.003 0
rs149768061 1 0.005 0.641 0.012 0
rs147345740 1 0.003 0.003 0
rs145889899 1 0.008 0
rs142900519 1 0
rs149114405 1
Correlation Matrix of Test Statistics with Case-Control Ratio of 2
rs143619888 rs150468103 rs141759859 rs149768061 rs147345740 rs145889899 rs142900519 rs149114405
rs143619888 1 0.006 0.006 0.021 0.006 0.014 0.001 0.001
rs150468103 1 0.001 0.005 0.001 0.003 0 0
rs141759859 1 0.005 0.001 0.003 0.003 0
rs149768061 1 0.005 0.636 0.011 0
rs147345740 1 0.004 0.003 0
rs145889899 1 0.008 0
rs142900519 1 0
rs149114405 1varied the case-control ratios for the other two studies. As
shown in Tables 1 and 2, the correlation matrices of the
test statistics are highly similar between the case-control
ratios of 1 and 2 (middle and bottom blocks) and are also
very similar to the correlation matrix of the genotypes in
the external reference panel (upper block). These results
corroborate the theoretical results given in Appendix A.
We evaluated the proposed methods based on single-
variant statistics with an internal or external reference,
denoted as SV-I and SV-E, respectively. As a benchmark,
we included the meta-analysis method based on multivar-
iate statistics (i.e., U and V), referred to as MV, which is a
gold standard because it is equivalent to joint analysis of
original data. We also included a naive method that sets
wj to 1=sej and R to the identity matrix; the naive method240 The American Journal of Human Genetics 93, 236–248, August 8assumes independence among variants and thus does not
use any reference data to estimate the LD. We constructed
the burden, VT, and SKAT tests. For the burden test, we
adopted the MAF threshold of 5%, which is commonly
called T5. For SKAT, we used the default weighted linear
kernel function. We considered the p values from the
Wald, score, and LR tests.
The type I error rates for quantitative and binary traits
when the summary statistics contain the standard error
estimates are shown in Tables 3 and 4, respectively. The
corresponding results when the summary statistics do
not contain the standard error estimates are shown in
Tables S1 and S2 available online. The two sets of results
are highly similar. For quantitative traits, both SV-I and
SV-E with the score, LR, or Wald test are as accurate as, 2013
Table 3. Type I Error Divided by the Nominal Significance Level for Quantitative Traits
Gene Test s2 MV
SV-I SV-E Naive
Score LR Wald Score LR Wald Score LR Wald
OR2T29 T5 0.5 0.97 0.98 0.99 1.00 0.96 0.97 0.98 75.83 75.98 76.15
1.0 1.00 1.01 1.01 1.02 0.98 0.98 1.00 75.69 75.85 76.00
VT 0.5 0.98 1.00 1.01 1.02 0.97 0.99 1.00 53.67 53.82 53.94
1.0 1.00 1.00 1.00 1.01 1.01 1.02 1.03 53.45 53.60 53.75
SKAT 0.5 0.97 0.95 0.97 0.98 0.95 0.96 0.98 19.27 19.38 19.49
1.0 1.00 1.01 1.01 1.02 0.99 1.00 1.01 19.20 19.29 19.37
LDLRAD1 T5 0.5 0.99 0.98 0.99 1.00 0.97 0.98 1.00 2.89 2.91 2.92
1.0 1.00 0.98 0.98 0.98 0.97 0.97 0.98 2.84 2.85 2.87
VT 0.5 1.01 1.04 1.04 1.05 1.02 1.03 1.04 2.94 2.97 2.99
1.0 1.02 1.05 1.06 1.06 1.01 1.02 1.02 2.99 3.01 3.02
SKAT 0.5 1.01 1.02 1.03 1.04 1.01 1.03 1.04 2.42 2.45 2.48
1.0 1.01 1.00 1.01 1.02 1.04 1.05 1.06 2.40 2.42 2.45
The summary statistics include the standard error estimates. The nominal significance level a¼ 0.001. s2 pertains to the error variance in studies 2 and 3. MV is the
gold standard. Each entry is based on 1,000,000 replicates.MV. For binary traits, SV-I tends to be more accurate than
SV-E and the Wald test tends to be more conservative
than the score and LR tests, especially for LDLRAD1. The
naive method has severe inflation of the type I error,
even for LDLRAD1, which has only one pair of cor-
related SNPs.
Figures 1 and 2 compare the powers of SV-I, SV-E, and
MV for quantitative and binary traits, respectively. The
results of the naive method are not shown because it has
inflated type I error and thus would not make a fair power
comparison. For quantitative traits, both SV-I and SV-E areTable 4. Type I Error Divided by the Nominal Significance Level for Bi
Gene Test Ratio MV
SV-I
Score LR Wald
OR2T29 T5 1.0 0.93 0.86 0.91 0.79
2.0 1.03 0.97 0.98 0.90
VT 1.0 0.93 0.87 0.93 0.77
2.0 1.04 1.01 1.00 0.88
SKAT 1.0 0.92 0.88 0.92 0.79
2.0 1.00 0.97 0.96 0.85
LDLRAD1 T5 1.0 0.88 0.81 0.88 0.70
2.0 1.03 1.05 0.99 0.88
VT 1.0 0.95 0.76 0.83 0.59
2.0 1.04 1.06 0.98 0.84
SKAT 1.0 0.90 0.81 0.92 0.63
2.0 0.93 0.91 0.93 0.68
The summary statistics include the standard error estimates. The nominal significa
gold standard. Each entry is based on 1,000,000 replicates.
The Ameras powerful as MV. For binary traits, SV-I and SV-E tend to
be slightly less powerful than MV; SV-E loses a little more
power than does SV-I because the wjs in SV-E are not as
stable as in SV-I. However, all the power differences are
very small. The results for SV-I and SV-E shown in Figures
1 and 2 pertain to the score test. For quantitative traits,
the results based on the Wald and LR tests are virtually
identical to those of the score test (data not shown). For
binary traits, the LR test yields slightly higher power
than the score test whereas the Wald test yields slightly
lower power; see Figures S1 and S2.nary Traits
SV-E Naive
Score LR Wald Score LR Wald
0.83 0.89 0.72 72.00 73.05 69.90
0.92 0.94 0.81 72.33 72.47 70.05
0.81 0.90 0.66 50.14 51.01 48.18
0.95 0.95 0.75 50.78 50.82 48.67
0.82 0.89 0.66 17.06 17.67 15.90
0.90 0.92 0.73 17.44 17.58 16.10
0.75 0.84 0.58 1.97 2.13 1.62
0.96 0.94 0.74 2.81 2.60 2.32
0.62 0.75 0.40 1.80 2.03 1.40
0.85 0.82 0.56 2.84 2.59 2.16
0.68 0.81 0.43 1.31 1.52 0.96
0.73 0.81 0.48 1.67 1.63 1.25
nce level a ¼ 0:001. Ratio is the case-control ratio in studies 2 and 3. MV is the
ican Journal of Human Genetics 93, 236–248, August 8, 2013 241
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Figure 1. Power of T5 at the Nominal
Significance Level a of 0.001 for Quantita-
tive Traits
s2 is the error variance for studies 2 and 3.
For SV-I and SV-E, single-variant p values
are based on the score test. Each power
estimate is based on 10,000 replicates.We also compared our methods to Fisher’s method of
combining p values. As shown in Figure S3, our methods
are substantially more powerful than Fisher’s method.
Finally, we examined the robustness of the proposed
methods to misspecification of the reference. We simu-
lated an external reference mimicking the HeartGO Afri-
can-American data from the ESP while still simulating
studies 1–3 from the ESP WHI data. In the HeartGO data,
the eight SNPs in LDLRAD1 have MAFs of 0.011, 0,
0.001, 0.016, 0, 0.01, 0.001, and 0 and genotype correla-
tions shown in Table S3. Clearly, theMAFs and LD patterns
differ considerably between the WHI and HeartGO data.
The simulation results for the proposed method based on
single-variant statistics with the misspecified external
reference, denoted by SV-E0, are shown in Table S4 and
Figure S4. Evidently, SV-E0 has reasonable control of the
type I error and is slightly less powerful than SV-E (using
the correct external reference).
GIANT Data
The GIANT consortium is an international collaboration
that seeks to discover genetic loci that modulate human
body size and shape, including height and measures of
obesity.19 The consortium was recently interested in242 The American Journal of Human Genetics 93, 236–248, August 8, 2013identifying genetic loci associated
with the extremes of height, body
mass index (BMI), and waist-hip ratio
adjusted by BMI.20 The investigators
from 50 GWASs were asked to
perform case-control comparisons,
treating individuals in the highest
5th percentile of the age- and sex-
adjusted distribution as cases and
those in the lowest 5th percentile as
controls, for a total of ~2.8 million
SNPs (genotyped or imputed by the
HapMap CEU population); the anal-
ysis was stratified by sex and disease
status and adjusted by age and prin-
cipal components for ancestry. The
summary results submitted to the
consortium contain the effect esti-
mates, the standard error estimates,
and the two-sided p values of the asso-
ciation tests for individual SNPs. The
associations with common SNPs had
been assessed by single-variant meta-
analysis; however, the informationon rare variants had not yet been exploited because of
the lack of proper analysis methods. With the proposed
methods, we conducted gene-level association tests of
rare variants through meta-analysis of the single-variant
summary results, focusing on the binary trait of extreme
height.
The 50 studies involved ~160,000 cohort members of
the European ancestry, among whom ~14,600 subjects
were selected as cases or controls for extreme height. The
sample sizes ranged from 812 to 14,594, with a median
of 13,413. We had access to the original data from one of
the cohorts, the ARIC study,21 which contains 8,108
cohort members and 812 subjects with extreme height.
Because the subjects from the 50 studies are all of the
same ancestry, we used the ARIC study as the internal refer-
ence. We annotated the genes in PLINK and filtered out
SNPs with MAFs >5% to end up with 10,851 genes con-
taining at least one SNP. Thus, the genome-wide signifi-
cance threshold based on the Bonferroni correction would
be ~5 3 106. The qq-plots for the SV-I and naive methods
are displayed in Figure 3. The naive method yielded exces-
sive positive findings and failed to identify some of the
genes identified by the SV-I method. Although the values
of the genomic control l were ~1.1 for the SV-I tests, the
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Figure 2. Power of T5 at the Nominal
Significance Level a of 0.001 for Binary
Traits
Ratio is the case-control ratio for studies 2
and 3. For SV-I and SV-E, single-variant p
values are based on the score test. Each po-
wer estimate is based on 10,000 replicates.modest inflation is unlikely attributed to the proposed
methods because the value of l was ~1.08 in the single-
variant meta-analysis (data not shown).
The SV-I T5 tests identified seven genes that pass the
genome-wide significance threshold of 5 3 106. The
results for those genes are shown in Table 5. One of the
genes (SNRPC [MIM 603522]) contains only one SNP, so
the gene-level and single-variant tests are the same. A sec-
ond gene (CRYBB1 [MIM 600929]) contains three SNPs,
oneofwhichhas apvalue that is the sameas the gene-based
p value and two of which have very large p values. A third
gene (SPEF2 [MIM 610172]) contains 15 SNPs, 9 of which
have p values similar to the gene-based p value and the
rest of which have large p values. For the remaining four
genes (ACAN [MIM 155760], CPNE1 [MIM 604205],
RBM12 [MIM 607179], and FAM134A), the gene-level
p values are smaller than the single-variant pvalues. Among
those four genes, only two have single-variant p values that
are less than 5 3 106. The foregoing results show that the
proposed method may boost the association signals.
The top gene in our analysis, ACAN, was previously iden-
tified by the GIANT consortium through the single-variant
meta-analysis for the full height distribution and the
extreme height;19,20 only SNP rs16942341 in this geneThe American Journal of Human Gwas reported.19 None of the other
genes in Table 5 have previously
been identified to be associated with
human height. All the SNPs identified
by previous single-variant meta-
analysis20 are relatively common,
i.e., MAFs R0:15, so those SNPs
were not included in the current
gene-level analysis.
For further comparisons, we per-
formed the single-variant meta-anal-
ysis of all the ~126,000 rare variants
that were included in the gene-level
analysis. We found that 19 of them
pass the Bonferroni threshold of
0:05=126;000z43107. Those 19
SNPs belong to five genes (ACAN,
DIS3L2 [MIM 614184], SNRPC,
UQCC [MIM 611797], and PLAG1
[MIM 603026]), only two of which
(ACAN and SNRPC) were identified
by the gene-level meta-analysis.
Thus, the proposed approach is com-
plementary to single-variant meta-analysis and can facilitate discoveries of rare variants for
complex human traits.Discussion
We presented a simple strategy to performmeta-analysis of
association results for rare variants in GWASs and
sequencing studies. Our approach is very convenient and
versatile because it requires only univariate statistics from
standard single-variant analysis and accommodates any
type of study and any type of trait. Our algorithms are
very fast. It took ~2 hr on an IBMHS22machine to perform
the meta-analysis of the GIANT data. The proposed
methods are implemented in the software MAGA: Meta-
Analysis of Gene-level Associations.
Alternative methods are being pursued independently
by other research groups. To our knowledge, those
methods all require multivariate statistics (i.e., the score
vector U and the information matrix V). It is more
challenging, both theoretically and computationally, to
develop meta-analysis methods based on univariate statis-
tics. We made a key observation that multivariate statistics
can be recovered from univariate statistics provided thatenetics 93, 236–248, August 8, 2013 243
Figure 3. Quantile-Quantile Plots of
log10(p Values) in the Meta-analysis
of the GIANT Extreme Height Studies
The genes that pass the genome-wide
significance threshold by the SV-I T5 tests
are marked. The p values <1012 are
truncated.the correlation matrix of the single-variant test statistics
can be determined. We rigorously justified the use of an
internal or external reference to estimate the correlation
matrix and derived statistically optimal and numerically
stable weighting schemes. From a practical point of view,
multivariate statistics can be collected only prospectively
in well-organized consortia. By contrast, our approach
requires only readily available univariate results from
single-variant analysis and is particularly attractive in the
retrospective analysis of existing studies.
Our approach requires a good estimate for the correla-
tion matrix of the single-variant test statistics. We showed244 The American Journal of Human Genetics 93, 236–248, August 8, 2013both theoretically and numerically
that the correlation matrix of the
test statistics is determined primarily
by the correlation matrix of the geno-
types and is not sensitive to the trait
variance, the case-control ratio, or
the distribution of covariates. The
studies to be combined need not to
be drawn from a single ancestral pop-
ulation. If the studies involve both
European and African ancestries,
then race-specific (internal or ex-
ternal) references can be used. It is
preferable to use an internal than an
external reference and to use a large
reference panel.
Our methods allow variants to be
polymorphic in only some of the
participating studies by setting the
entries in the score vector and infor-
mation matrix corresponding to a
nonpolymorphic variant to zero.
In our current implementation, we
disregard the variants that are not
polymorphic in the reference panel.
An alternative strategy is to assume
that such rare variants are indepen-
dent of others so that the correspond-
ing entries in the correlation matrix
R can be set to zero.
Meta-analysis based on score tests
performs better than that of LR or
Wald tests, especially for binary traits
with rare variants. Wemake use of the
standardized test statistics or p values
rather than the score statistics (i.e.,
components of U) and their variances(i.e., diagonal elements of V). The latter, together with the
correlationmatrix, would completely recover themultivar-
iate statistics. We do not require score statistics and their
variances because they are not available in standard soft-
ware packages such as SAS and R. However, score statistics
and their variances can be obtained from special computer
programs, such as SCORE-Seq12 and SCORE-SeqTDS.23 We
recommend that such information be included in the sum-
mary results of single-variant analysis in the future, which
will lead to more accurate meta-analysis.
In the current practice, a variant that does not have a
valid effect estimate is excluded from the summary results
Table 5. Top Genes Identified by T5 in the SV-I Meta-analysis
Gene/SNP Chr Position MAF Effect SE p Value
ACAN 8.0 3 1011
rs16942341 15 87189909 0.026 0.508 0.082 3.7 3 1010
rs16942383 15 87206056 0.034 0.437 0.070 1.3 3 109
rs12385976 15 87205096 0.042 0.358 0.060 2.6 3 109
rs8024016 15 87209085 0.038 0.356 0.060 8.0 3 109
rs3784757 15 87204408 0.031 0.430 0.071 1.5 3 108
SNRPC 3.1 3 108
rs9462016 6 34847768 0.046 0.263 0.055 3.1 3 108
CPNE1 4.9 3 107
rs6060540 20 33711263 0.048 0.216 0.054 7.0 3 105
rs17426738 20 33701348 0.047 0.219 0.055 7.0 3 105
rs6060536 20 33700401 0.047 0.219 0.055 7.1 3 105
rs926994 20 33684437 0.048 0.215 0.055 7.6 3 105
rs2230219 20 33682894 0.048 0.215 0.055 7.6 3 105
rs6121021 20 33715852 0.048 0.216 0.055 7.9 3 105
rs17427233 20 33709531 0.047 0.217 0.055 7.9 3 105
rs6058292 20 33712183 0.048 0.217 0.055 8.0 3 105
rs17426419 20 33693059 0.047 0.208 0.054 1.1 3 104
rs6121019 20 33714062 0.048 0.210 0.055 1.2 3 104
rs17092957 20 33715359 0.033 0.201 0.071 4.2 3 103
rs7272885 20 33690567 0.033 0.203 0.071 4.9 3 103
rs17092885 20 33693038 0.033 0.198 0.071 6.0 3 103
rs17092937 20 33707024 0.033 0.193 0.071 6.7 3 103
rs17092945 20 33708972 0.033 0.198 0.071 6.9 3 103
rs8050 20 33700638 0.033 0.197 0.071 7.4 3 103
rs17092915 20 33702884 0.033 0.196 0.071 7.4 3 103
rs17092869 20 33687762 0.046 0.190 0.090 1.4 3 102
rs2425068 20 33678137 0.045 0.048 0.080 4.3 3 101
RBM12 1.1 3 106
Subset of CPNE1 SNPs
CRYBB1 1.1 3 106
rs2301439 22 25327383 0.019 0.789 0.184 1.1 3 106
rs5752354 22 25332648 0.007 0.231 0.172 4.6 3 102
rs7290642 22 25331364 0.010 0.176 0.110 8.1 3 102
FAM134A 1.2 3 106
rs2293072 2 219753698 0.041 0.299 0.063 1.7 3 106
rs2385393 2 219757631 0.003 0.908 0.608 3.3 3 101
SPEF2 4.6 3 106
rs6862961 5 35736129 0.021 0.392 0.088 4.3 3 106
rs7714298 5 35760267 0.021 0.385 0.088 5.4 3 106
rs10061088 5 35759618 0.021 0.386 0.088 5.5 3 106
rs10058394 5 35757834 0.021 0.384 0.088 6.0 3 106
Table 5. Continued
Gene/SNP Chr Position MAF Effect SE p Value
rs10051352 5 35757747 0.021 0.383 0.088 6.8 3 106
rs10071847 5 35757450 0.021 0.383 0.088 7.6 3 106
rs7703587 5 35756245 0.021 0.382 0.088 7.6 3 106
rs7703605 5 35756281 0.021 0.383 0.088 8.2 3 106
rs6891096 5 35733720 0.021 0.387 0.089 1.2 3 105
rs2361394 5 35836304 0.044 0.013 0.017 8.7 3 102
rs11742689 5 35841905 0.041 0.099 0.067 1.8 3 101
rs11740118 5 35714128 0.047 0.094 0.060 2.0 3 101
rs7725710 5 35732941 0.023 0.117 0.174 3.3 3 101
rs286441 5 35673325 0.036 0.022 0.060 9.7 3 101
rs12514911 5 35662699 0.036 0.022 0.060 9.7 3 101
The Amerfile. For a case-control study, the log odds ratio cannot be
estimated if there are nomutations in either the case group
or the control group. However, such a study contains valu-
able information about the association. To solve this
dilemma, we again recommend that researchers include
the score statistics and their variances in the summary re-
sults, which can be combined efficiently in meta-analysis.
Another (less attractive) solution would be to report the p
value of an asymptotic or exact test and the direction of the
association. These two pieces of information can be used to
construct an approximate standard-normal statistic, and
the sample size and MAF can be used to estimate the vari-
ance for the weighting scheme.
Although we have focused on studies of unrelated indi-
viduals with quantitative and binary traits, the proposed
methods are applicable to other study designs and other
traits, such as family studies, extreme-trait sampling,
ordinal traits, and (potentially censored) ages at disease
onset. In addition, the proposed methods can be extended
to incorporate heterogeneous effects among studies by
defining the burden statistic as
PL
l¼1ðxðlÞTU ðlÞÞ2 and the
SKAT statistic as
PL
l¼1U
ðlÞTWðlÞUðlÞ, where xðlÞ and WðlÞ
pertain to the lth study.
In summary, we developed a simple and practical tool to
perform meta-analysis of rare variants based on single-
variant statistics. We showed both theoretically and
numerically that the proposed approach has correct type
I error and is as powerful as joint analysis of individual
participant data (provided that an appropriate reference
panel is available). With the GIANT data, we demonstrated
that the proposed approach can facilitate the discoveries of
rare variants associated with complex human traits.Appendix A
The joint distributions of ðZ1;.;ZmÞT for the Wald, score,
and LR tests are asymptotically the same.24 Thus, it suffices
to evaluate the covariance matrix of ðZ1;.;ZmÞT in termsican Journal of Human Genetics 93, 236–248, August 8, 2013 245
of the correlation matrix of U. Without loss of generality,
we center the Gis at their sample mean.
In the absence of covariates, Equation 2 reduces to
V ¼ abf1b00ðbgÞXn
i¼1
GiG
T
i ;
so the corresponding R is equal to the sample correla-
tion matrix of G. If there exist covariates but they are
independent of or weakly correlated with genetic vari-
ables, then
Vz a
bf1
n1Pn
i¼1
b00ðbgTXiÞPn
i¼1
GiG
T
i 

n1
Pn
i¼1
Gi
Pn
i¼1
b00ðbgTXiÞXTi Pn
i¼1
b00ðbgTXiÞXiXTi 1


n1
Pn
i¼1
b00ðbgTXiÞXiPn
i¼1
GTi

;
¼ abf1n1Pn
i¼1
b00ðbgTXiÞPn
i¼1
GiG
T
i ;
where the second equality follows from the centering of
the genotype values. Thus, the corresponding R is approx-
imately equal to the correlationmatrix ofG. In conclusion,
two studies with the same LD structure will have
essentially the same correlation matrix R if there are no
covariates or if the covariates and genetic variables are
independent or weakly correlated.
We now consider the uncommon situation in which
covariates are strongly correlated with genetic variables.
For the linear regression analysis of quantitative traits,
aðfÞ ¼ s2 and b00ðzÞ ¼ 1. Thus,
V ¼ bs2(Xn
i¼1
GiG
T
i 
 Xn
i¼1
GiX
T
i
! Xn
i¼1
XiX
T
i
!1 Xn
i¼1
XiG
T
i
!)
:
This implies that two studies with the same joint distribu-
tion of ðG;XÞ will have the same R even when their trait
variances ðs2Þ are different. For the logistic regression anal-
ysis of case-control data,
V ¼
Xn
i¼1
v
bgTXiGiGTi 
(Xn
i¼1
v
bgTXiGiXTi
)

(Xn
i¼1
v
bgTXiXiXTi
)1(Xn
i¼1
v
bgTXiXiGTi
)
;
where vðzÞ ¼ ez=ð1þ ezÞ2. Thus, two studies with the
same value of g and same joint distribution of ðG;XÞ will
have the same R. Note that the value of vðbgTXiÞ does not
depend strongly on the covariate values provided that
the case-control ratio is not close to 0 or 1. Thus,
vðbgTXiÞzvðbg0Þ, where bg0 is the intercept component ofbg. Therefore,
Vz vðbg0Þ
(Xn
i¼1
GiG
T
i 
Xn
i¼1
GiX
T
i
 Xn
i¼1
XiX
T
i
!1Xn
i¼1
XiG
T
i
)
;246 The American Journal of Human Genetics 93, 236–248, August 8which implies that two studies with the same joint
distribution of ðG;XÞ will have approximately the same R
even when their case-control ratios are different.Supplemental Data
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